Merck KGaA to Acquire Rapid Micro Biosystemsn in All-Cash Deal
Merck KGaA to acquire Rapid Micro Biosystems for $0.75/share in all-cash deal, strengthening pharmaceutical quality control automation via the Growth Direc
Research Desk
Rapid Micro Biosystems, Inc. (Nasdaq: RPID), a life sciences technology company providing automation solutions for pharmaceutical manufacturing and quality control, announced on November 16, 2026, that it has signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany.
Under the terms of the agreement, Merck KGaA will acquire all outstanding shares of Rapid Micro Biosystems at a price of USD 0.75 per share in an all-cash transaction. The announcement was made from the company's headquarters in Lexington, Massachusetts, where Rapid Micro Biosystems is based. The company also maintains U.S. manufacturing operations in Lowell, Massachusetts, along with global locations in Switzerland, Germany, and the Netherlands.
Leadership Perspectives on the Deal
Robert Spignesi, President and CEO of Rapid Micro Biosystems, pointed to the partnership the two companies have developed over the preceding 18 months. "Over the past 18 months, we have built a strong partnership with Merck KGaA, Darmstadt, Germany, centered on a shared commitment to innovation and helping customers modernize and automate their quality-control workflows," Spignesi said.
Spignesi noted that Rapid Micro Biosystems has established its Growth Direct platform as the leading solution for automating microbial quality control, with most of the world's top pharmaceutical manufacturers as customers. He expressed confidence that joining the Life Science business of Merck KGaA would significantly expand the Growth Direct platform's reach and more fully serve the combined global customer base.
On the acquirer's side, Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany, emphasized the strategic fit. "Quality control is essential to the reliable manufacture of medicines," Carli said.
"Our customers need reliable results faster, more efficient quality-control workflows and robust data integrity to support regulatory compliance. Rapid Micro Biosystems will strengthen our ability to meet those needs, building on our existing offering and bringing greater automation to a critical step in pharmaceutical manufacturing."
Transaction Structure and Expected Closing
The transaction is expected to close in December 2026. The closing is subject to the successful completion of a tender offer, including satisfaction of the minimum tender condition, as well as other customary closing conditions.
Following completion of the transaction, Rapid Micro Biosystems will become part of the Life Science business of Merck KGaA, Darmstadt, Germany. The tender offer process will involve Merck KGaA, Darmstadt, Germany and EMD Holdings NewCo II, Inc. ("Purchaser") filing a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission, while Rapid Micro Biosystems will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC.
Once filed, these documents will be available at no charge on the SEC's website at www.sec.gov, through Merck KGaA's website under the "Investors" section, and through Rapid Micro Biosystems' website under the "Investor Relations" section. Shareholders will also be able to obtain the documents at no cost through the information agent for the tender offer.
Advisors to the Transaction
Perella Weinberg Partners is serving as financial advisor to Rapid Micro Biosystems, and Goodwin Procter LLP is serving as the company's legal counsel in connection with the transaction.
About Rapid Micro Biosystems and the Growth Direct Platform
Rapid Micro Biosystems describes itself as an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products. The company's customers produce a range of healthcare products, including biologics, vaccines, cell and gene therapies, and sterile injectables.
The company's flagship product, the Growth Direct system, automates and modernizes manual microbial quality control (MQC) testing workflows used in large and complex pharmaceutical manufacturing operations across the globe. According to the company, the Growth Direct system brings the quality control lab to the manufacturing floor, delivering faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure a safe and consistent supply of healthcare products.
Rapid Micro Biosystems has stated that it intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and complying with its disclosure obligations under Regulation FD, and it advises investors to monitor the website in addition to following press releases, filings with the SEC, public conference calls, presentations and webcasts.
Regulatory Disclosures
The company noted in its announcement that the tender offer described in the communication had not yet commenced at the time of the release, and that the communication itself is neither an offer to purchase nor a solicitation of an offer to sell securities.
The announcement included standard forward-looking statements language regarding the potential acquisition. Investors and security holders were strongly advised to read the tender offer statement, including the offer to purchase, letter of transmittal and related tender offer documents, as well as the related solicitation/recommendation statement on Schedule 14D-9, when they become available, because those documents will contain important information about the transaction.
Tracked in the database
Mergers & Acquisitions · North America
Mergers & Acquisitions
North America
Chemical
17 November 2026
4 min read
Tagged
Also read
Lonza to Acquire Merck's US CDMO Business Across Five Sites
Supernus Completes Indivior Merger to Form 11-Product CNS Pharmaceutical Company in the US
LGM Pharma Expands GLP Bioanalysis and Impurity Testing Capabilities With Sannova Analytical Integration in New Jersey, US
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.